NEWAMSTERDAM PHARMA CO NV (NAMS) Stock Income Statement
USA - NASDAQ:NAMS - NL00150012L7 - Common Stock
37.38 USD
+0.38 (+1.03%)
| 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|
| Revenue | 97.50M | 0.00 | 0.00 | |||
| Operating Expenses | 101.44M | 1.37M | 127.70K | |||
| Research and Development | 82.23M | 25.03M | 4.04M | |||
| Selling, General, and Administrative Expenses | 13.93M | 1.37M | 127.70K | |||
| Operating Income | -3.94M | -1.37M | -127.70K | |||
| Interest Income/Expense | -10.49M | 4.54M | 169.10K | |||
| Other Income/Expense | N/A | 1.00M | N/A | |||
| Non Recurring Items | -63.62M | N/A | N/A | |||
| Income Before Taxes | -78.05M | 4.18M | 41.50K | |||
| Income Tax | 0.00 | 0.00 | 0.00 | |||
| Net Income | -78.05M | 4.18M | 41.50K | |||
| EBITDA | -3.87M | -1.35M | -126.70K | |||
| Per Share Data | ||||||
| EPS Diluted Total Ops | -0.95 | 0.24 | 0.00 | |||
| Statistics | ||||||
| Profit Margin | -80.05% | N/A | N/A | |||
| Operating Profit Margin | -4.04% | N/A | N/A | |||
All data in USD